Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

NCT03368170 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Mesdopetam (IRL790)

Sponsor

Integrative Research Laboratories AB

Collaborators

[object Object]